Correction: LabTech launches MicroStreak in US
Friday, 13 June, 2008
In our online story LabTech launches MicroStreak in the US on June 11, we incorrectly stated that LabTech Systems had received royalties from sales.
The company is anticipating royalties but they have not been received yet. LabTech Systems has instead received licence payments of $4.9 million to date from licencee bioMerieux, and is entitled to receive up to a total of $11.2 million.
The original story has been corrected. We apologise for the error.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
